The market for weight loss medications is expected to grow to 190 billion dollars by 2035, with Eli Lilly considered the market leader, while Novo Nordisk is fighting for a comeback and investors are interested in a broader approach to pharmaceutical stocks that goes beyond just weight loss. (translated)










